Each organ becomes a preferred sequestration site because of its unique biology — its transporters, metabolic activity, storage capacity, and inability to fully clear the toxin through primary detox routes.
This toxin-to-organ mapping gives us an actionable way to treat specific cancers. If someone has breast cancer, we can advise them to reduce their excess estrogen, damaged oils, and oxalates — whereas if someone has liver cancer, we can advise them to reduce their excess iron, ethanol, fructose, and mycotoxins.
The following table below elaborates on this idea further, identifying sets of toxins with specific organs, and explains why the body chooses that organ for cancer tumors.
Metastasis: Not Spread, But Strategic Expansion of Sequestration Sites
One of the most misunderstood aspects of cancer is metastasis. Conventional medicine describes it as malignant cells “spreading” and colonizing distant organs, as if the body had lost all control. In TST, metastasis is seen very differently: it is the body’s intelligent decision to establish new sequestration vaults when the original tumor can no longer contain the toxic load or when certain toxins need to be isolated in different tissues.
When the primary tumor can no longer contain the toxic burden, the body builds additional storage vaults in distant organs. Metastasis is the body’s continued effort to isolate and sequester excess toxins.
Just as the primary tumor forms in the organ best suited to handle the dominant toxic load, metastatic sites follow the same logic on a systemic scale:
● Bone is frequently chosen when the toxic metal burden is high — bone marrow has enormous storage capacity and natural affinity for metal (e.g., iron) sequestration.
● Liver becomes a common secondary site because it is already the body’s master detox organ and has robust machinery for handling a wide range of toxins.
● Lungs are often targeted for lipid-soluble or airborne-derived toxins, as they provide large surface area and high blood flow for rapid sequestration